Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
Priya Singhal sold 3,806 shares of BIIB on 19 May at $126.25 per share, worth a total of $481K. They now own 5,427 BIIB shares, or a 41% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
